PolyPeptide Group AG (PPGN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.150x

Based on the latest financial reports, PolyPeptide Group AG (PPGN) has a cash flow conversion efficiency ratio of 0.150x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF49.66 Million ≈ $62.78 Million USD) by net assets (CHF330.99 Million ≈ $418.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PPGN equity financing ratio to measure how much of total assets are equity-financed.

PolyPeptide Group AG - Cash Flow Conversion Efficiency Trend (2018–2024)

This chart illustrates how PolyPeptide Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PolyPeptide Group AG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

PolyPeptide Group AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PolyPeptide Group AG ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Grocery Outlet Holding Corp NASDAQ:GO	0.091x
Basler Aktiengesellschaft XETRA:BSL	0.052x
Fujian Longma Envi Sanitation SHG:603686	0.030x
Prima Andalan Mandiri Tbk PT JK:MCOL	0.113x
Africa Israel Residences Ltd TA:AFRE	-0.033x
Hyperliquid Strategies Inc Common Stock NASDAQ:PURR	N/A
Anhui Sierte Fertilizer Industry Ltd Co SHE:002538	0.024x
Link Mobility Group Holding ASA OL:LINK	0.122x

Annual Cash Flow Conversion Efficiency for PolyPeptide Group AG (2018–2024)

The table below shows the annual cash flow conversion efficiency of PolyPeptide Group AG from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see PolyPeptide Group AG (PPGN) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF357.24 Million ≈ $451.65 Million	CHF89.40 Million ≈ $113.02 Million	0.250x	+161.48%
2023-12-31	CHF381.23 Million ≈ $481.97 Million	CHF36.48 Million ≈ $46.13 Million	0.096x	+639.13%
2022-12-31	CHF421.68 Million ≈ $533.11 Million	CHF5.46 Million ≈ $6.90 Million	0.013x	-90.49%
2021-12-31	CHF421.17 Million ≈ $532.48 Million	CHF57.35 Million ≈ $72.51 Million	0.136x	-51.11%
2020-12-31	CHF177.66 Million ≈ $224.61 Million	CHF49.48 Million ≈ $62.56 Million	0.279x	-25.15%
2019-12-31	CHF149.42 Million ≈ $188.90 Million	CHF55.60 Million ≈ $70.29 Million	0.372x	+139.51%
2018-12-31	CHF147.67 Million ≈ $186.70 Million	CHF22.94 Million ≈ $29.01 Million	0.155x	--

About PolyPeptide Group AG

SW:PPGN Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$2.06 Billion

CHF1.63 Billion CHF

Market Cap Rank

#9958 Global

#125 in Switzerland

Share Price

CHF49.35

Change (1 day)

-0.10%

52-Week Range

CHF20.50 - CHF49.40

All Time High

CHF143.30